Accession Number:

ADA470579

Title:

Breast Tumor Detection and Treatment Using Tarvacin Labeled with Arsenic Radionuclides

Descriptive Note:

Annual rept. 1 Apr 2006-31 Mar 2007

Corporate Author:

TEXAS UNIV SOUTHWESTERN MEDICAL SCHOOL AT DALLAS

Personal Author(s):

Report Date:

2007-04-01

Pagination or Media Count:

18.0

Abstract:

We will generate a novel approach for detection and therapy of advanced breast cancer based on three fundamentally novel discoveries and concepts. The first critical component exploits a novel antibody, which targets phosphatidylserine PS, expressed on tumor vasculature. In collaboration with Peregrine Pharmaceuticals, this agent has been chimerized and is being developed for clinical trials as bavituximab formerly TM. Normally, exclusively resides on the cytosolic leaflet of the plasma membrane, but in tumors PS becomes externalized providing a viable target. The agent not only targets various tumors, but also induces vascular damage and tumor regression with minimal accompanying toxicity. The second component is the identification of diverse arsenic radionuclides suitable for imaging based on PET and radio immunotherapy together with new means of isolating the radionuclides. Importantly, the antibodies can be effectively labeled forming viable products of high specific radiochemical and biological activity. Thirdly, our program brings together pharmacological and radiochemical expertise to facilitate collaboration, progress, and synergy. This project will develop a single agent bavituximab for tumor detection, dosimetry, and therapy based on differential properties of arsenic radionuclides, but exploiting a single chemistry.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research
  • Radiobiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE